{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:55:39Z","timestamp":1793904939216,"version":"4.8.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth Analg Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the last decades, several adjunctive treatments have been proposed to reduce mortality in septic shock patients. Unfortunately, mortality due to sepsis and septic shock remains elevated and NO trials evaluating adjunctive therapies were able to demonstrate any clear benefit. In light of the lack of evidence and conflicting results from previous studies, in this multidisciplinary consensus, the authors considered the rational, recent investigations and potential clinical benefits of targeted adjunctive therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A panel of multidisciplinary experts defined clinical phenotypes, treatments and outcomes of greater interest in the field of adjunctive therapies for sepsis and septic shock. After an extensive systematic literature review, the appropriateness of each treatment for each clinical phenotype was determined using the modified RAND\/UCLA appropriateness method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The consensus identified two distinct clinical phenotypes: patients with overwhelming shock and patients with immune paralysis. Six different adjunctive treatments were considered the most frequently used and promising: (i) corticosteroids, (ii) blood purification, (iii) immunoglobulins, (iv) granulocyte\/monocyte colony-stimulating factor and (v) specific immune therapy (i.e. interferon-gamma, IL7 and AntiPD1). Agreement was achieved in 70% of the 25 clinical questions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although clinical evidence is lacking, adjunctive therapies are often employed in the treatment of sepsis. To address this gap in knowledge, a panel of national experts has provided a structured consensus on the appropriate use of these treatments in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s44158-024-00165-3","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T10:01:22Z","timestamp":1714471282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adjunctive immunotherapeutic agents in patients with sepsis and septic shock: a multidisciplinary consensus of 23"],"prefix":"10.1186","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-0829","authenticated-orcid":false,"given":"Massimo","family":"Girardis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Coloretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Berlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Busani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cortegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Donadello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abele","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Forfori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Grasselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Montrucchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pasero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Viaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tumbarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"165_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","volume":"34","author":"J-L Vincent","year":"2006","unstructured":"Vincent J-L et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344\u2013353","journal-title":"Crit Care Med"},{"key":"165_CR2","first-page":"993","volume":"79","author":"Y Sakr","year":"2013","unstructured":"Sakr Y et al (2013) Epidemiology and outcome of sepsis syndromes in Italian ICUs: a muticentre, observational cohort study in the region of Piedmont. Minerva Anestesiol 79:993\u20131002","journal-title":"Minerva Anestesiol"},{"key":"165_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s13054-015-1164-6","volume":"19","author":"M Shankar-Hari","year":"2015","unstructured":"Shankar-Hari M et al (2015) Judging quality of current septic shock definitions and criteria. Crit Care 19:445","journal-title":"Crit Care"},{"key":"165_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181\u20131247","journal-title":"Intensive Care Med"},{"issue":"1","key":"165_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s13054-021-03813-0","volume":"25","author":"V Jl","year":"2021","unstructured":"Jl V et al (2021) Equilibrating SSC guidelines with individualized care. Crit Care Lond Engl. 25(1):397","journal-title":"Crit Care Lond Engl."},{"key":"165_CR6","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND\/UCLA Appropriateness Method User's Manual. Santa Monica: RAND Corporation; 2001. https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html."},{"key":"165_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000324022","volume":"17","author":"DLW Chong","year":"2011","unstructured":"Chong DLW, Sriskandan S (2011) Pro-inflammatory mechanisms in sepsis. Contrib Microbiol 17:86\u2013107","journal-title":"Contrib Microbiol"},{"key":"165_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJM198808183190703","volume":"319","author":"E Girardin","year":"1988","unstructured":"Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397\u2013400","journal-title":"N Engl J Med"},{"key":"165_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss RS et al (2016) Sepsis and septic shock. Nat Rev Dis Primer 2:1\u201321","journal-title":"Nat Rev Dis Primer"},{"key":"165_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/cc1825","volume":"7","author":"M Riewald","year":"2003","unstructured":"Riewald M, Ruf W (2003) Science review: Role of coagulation protease cascades in sepsis. Crit Care 7:123\u2013129","journal-title":"Crit Care"},{"key":"165_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.it.2012.09.004","volume":"34","author":"M Bosmann","year":"2013","unstructured":"Bosmann M, Ward PA (2013) The inflammatory response in sepsis. Trends Immunol 34:129\u2013136","journal-title":"Trends Immunol"},{"key":"165_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40560-015-0112-5","volume":"3","author":"R Sato","year":"2015","unstructured":"Sato R, Nasu M (2015) A review of sepsis-induced cardiomyopathy. J Intensive Care 3:48","journal-title":"J Intensive Care"},{"key":"165_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S1473-3099(13)70001-X","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13:260\u2013268","journal-title":"Lancet Infect Dis"},{"key":"165_CR14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nature01326","volume":"420","author":"J Cohen","year":"2002","unstructured":"Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885\u2013891","journal-title":"Nature"},{"key":"165_CR15","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1213\/ane.0b013e318195e11d","volume":"108","author":"C Torgersen","year":"2009","unstructured":"Torgersen C et al (2009) Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 108:1841\u20131847","journal-title":"Anesth Analg"},{"key":"165_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/cid\/cix120","volume":"64","author":"DSY Ong","year":"2017","unstructured":"Ong DSY et al (2017) Epidemiology of Multiple Herpes Viremia in Previously Immunocompetent Patients With Septic Shock. Clin Infect Dis Off Publ Infect Dis Soc Am 64:1204\u20131210","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"165_CR17","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1097\/CCM.0b013e318256bb99","volume":"40","author":"S Kethireddy","year":"2012","unstructured":"Kethireddy S, Kumar A (2012) Mortality due to septic shock following early, appropriate antibiotic therapy: can we do better?*. Crit Care Med 40:2228\u20132229","journal-title":"Crit Care Med"},{"key":"165_CR18","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1186\/cc10332","volume":"15","author":"GP Otto","year":"2011","unstructured":"Otto GP et al (2011) The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care Lond Engl 15:R183","journal-title":"Crit Care Lond Engl"},{"key":"165_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13613-015-0058-8","volume":"5","author":"F Daviaud","year":"2015","unstructured":"Daviaud F et al (2015) Timing and causes of death in septic shock. Ann Intensive Care 5:16","journal-title":"Ann Intensive Care"},{"key":"165_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13054-017-1803-1","volume":"21","author":"J Textoris","year":"2017","unstructured":"Textoris J, Mallet F (2017) Immunosuppression and herpes viral reactivation in intensive care unit patients: one size does not fit all. Crit Care Lond Engl 21:230","journal-title":"Crit Care Lond Engl"},{"key":"165_CR21","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nri3552","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862\u2013874","journal-title":"Nat Rev Immunol"},{"key":"165_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1164\/rccm.201011-1897CI","volume":"185","author":"GP Patel","year":"2012","unstructured":"Patel GP, Balk RA (2012) Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 185:133\u2013139","journal-title":"Am J Respir Crit Care Med"},{"key":"165_CR23","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1210\/jc.2006-0674","volume":"91","author":"BM Arafah","year":"2006","unstructured":"Arafah BM (2006) Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab 91:3725\u20133745","journal-title":"J Clin Endocrinol Metab"},{"key":"165_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7326\/0003-4819-141-1-200407060-00014","volume":"141","author":"PC Minneci","year":"2004","unstructured":"Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C (2004) Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141:47\u201356","journal-title":"Ann Intern Med"},{"key":"165_CR25","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1007\/s00134-015-3899-6","volume":"41","author":"M Volbeda","year":"2015","unstructured":"Volbeda M et al (2015) Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 41:1220\u20131234","journal-title":"Intensive Care Med"},{"issue":"12","key":"165_CR26","first-page":"CD002243","volume":"2015","author":"D Annane","year":"2015","unstructured":"Annane D et al (2015) Corticosteroids for treating sepsis. Cochrane Database Syst. Rev 2015(12):CD002243","journal-title":"Cochrane Database Syst. Rev"},{"key":"165_CR27","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1097\/01.CCM.0000186370.78639.23","volume":"33","author":"M Oppert","year":"2005","unstructured":"Oppert M et al (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33:2457\u20132464","journal-title":"Crit Care Med"},{"issue":"178","key":"165_CR28","first-page":"1845","volume":"1950","author":"MD de Kruif","year":"2007","unstructured":"de Kruif MD et al (2007) Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol Baltim Md 1950(178):1845\u20131851","journal-title":"J Immunol Baltim Md"},{"key":"165_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13054-017-1659-4","volume":"21","author":"B Gibbison","year":"2017","unstructured":"Gibbison B et al (2017) Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care Lond Engl 21:78","journal-title":"Crit Care Lond Engl"},{"key":"165_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CCM.0b013e3181961ace","volume":"37","author":"JA Russell","year":"2009","unstructured":"Russell JA et al (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock*: Crit. Care Med 37:811\u2013818","journal-title":"Care Med"},{"key":"165_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1705835","volume":"378","author":"B Venkatesh","year":"2018","unstructured":"Venkatesh B et al (2018) Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med 378:797\u2013808","journal-title":"N Engl J Med"},{"key":"165_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1705716","volume":"378","author":"D Annane","year":"2018","unstructured":"Annane D et al (2018) Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 378:809\u2013818","journal-title":"N Engl J Med"},{"key":"165_CR33","first-page":"134","volume":"275","author":"MJ Fine","year":"1996","unstructured":"Fine MJ et al (1996) Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis JAMA 275:134\u2013141","journal-title":"A meta-analysis JAMA"},{"key":"165_CR34","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(11)60607-7","volume":"377","author":"SCA Meijvis","year":"2011","unstructured":"Meijvis SCA et al (2011) Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl 377:2023\u20132030","journal-title":"Lancet Lond Engl"},{"key":"165_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejcdt.2013.03.009","volume":"62","author":"R Nafae","year":"2013","unstructured":"Nafae R, Ragab M, Amany F, Rashed S (2013) Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 62:439\u2013445","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"165_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4236\/pp.2011.22009","volume":"2","author":"NA Sabry","year":"2011","unstructured":"Sabry NA, Omar EE-D (2011) Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings. Pharmacol Amp Pharm 2:73\u201381","journal-title":"Pharmacol Amp Pharm"},{"key":"165_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","volume":"171","author":"M Confalonieri","year":"2005","unstructured":"Confalonieri M et al (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171:242\u2013248","journal-title":"Am J Respir Crit Care Med"},{"key":"165_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.88","volume":"313","author":"A Torres","year":"2015","unstructured":"Torres A et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:677\u2013686","journal-title":"JAMA"},{"key":"165_CR39","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","volume":"385","author":"CA Blum","year":"2015","unstructured":"Blum CA et al (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Lond Engl 385:1511\u20131518","journal-title":"Lancet Lond Engl"},{"key":"165_CR40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00134-022-06684-3","volume":"48","author":"GU Meduri","year":"2022","unstructured":"Meduri GU et al (2022) Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med 48:1009\u20131023","journal-title":"Intensive Care Med"},{"key":"165_CR41","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"P-F Dequin","year":"2023","unstructured":"Dequin P-F et al (2023) Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med 388:1931\u20131941","journal-title":"N Engl J Med"},{"key":"165_CR42","doi-asserted-by":"publisher","unstructured":"Martin-Loeches, I. et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 1\u201318 (2023) doi:https:\/\/doi.org\/10.1007\/s00134-023-07033-8.","DOI":"10.1007\/s00134-023-07033-8"},{"key":"165_CR43","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1007\/s11606-023-08203-6","volume":"38","author":"T Pitre","year":"2023","unstructured":"Pitre T et al (2023) Corticosteroids in Community-Acquired Bacterial Pneumonia: a Systematic Review, Pairwise and Dose-Response Meta-Analysis. J Gen Intern Med 38:2593\u20132606","journal-title":"J Gen Intern Med"},{"key":"165_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13054-019-2395-8","volume":"23","author":"Y-N Ni","year":"2019","unstructured":"Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A (2019) The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care Lond Engl 23:99","journal-title":"Crit Care Lond Engl"},{"key":"165_CR45","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1097\/CCM.0000000000004093","volume":"48","author":"L.E Lansbury","year":"2020","unstructured":"An Updated Cochrane Systematic Review and Meta-analysis, Lansbury L.E, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W (2020) Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit. Care Med. 48:e98\u2013e106","journal-title":"Crit. Care Med."},{"key":"165_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2165\/00003495-200666040-00002","volume":"66","author":"D van de Beek","year":"2006","unstructured":"van de Beek D, de Gans J (2006) Dexamethasone in adults with community-acquired bacterial meningitis. Drugs 66:415\u2013427","journal-title":"Drugs"},{"key":"165_CR47","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJMoa021334","volume":"347","author":"J de Gans","year":"2002","unstructured":"de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators (2002) Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med 347:1549\u20131556","journal-title":"N. Engl. J. Med"},{"key":"165_CR48","doi-asserted-by":"publisher","first-page":"101922","DOI":"10.1016\/j.eclinm.2023.101922","volume":"58","author":"M.C Brouwer","year":"2023","unstructured":"Brouwer M.C, van de Beek D (2023) Adjunctive dexamethasone treatment in adults with listeria monocytogenes meningitis: a prospective nationwide cohort study. eClinicalMedicine 58:101922","journal-title":"eClinicalMedicine"},{"key":"165_CR49","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/infdis\/151.3.528","volume":"151","author":"MG T\u00e4uber","year":"1985","unstructured":"T\u00e4uber MG, Khayam-Bashi H, Sande MA (1985) Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. J Infect Dis 151:528\u2013534","journal-title":"J Infect Dis"},{"issue":"9","key":"165_CR50","first-page":"CD004405","volume":"2015","author":"M.C Brouwer","year":"2015","unstructured":"Brouwer M.C, McIntyre P, Prasad K, van de Beek D (2015) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev 2015(9):CD004405","journal-title":"Cochrane Database Syst. Rev"},{"key":"165_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","volume":"45","author":"A Rhodes","year":"2017","unstructured":"Rhodes A et al (2017) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 45:486\u2013552","journal-title":"Crit Care Med"},{"key":"165_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000333837","volume":"33","author":"PM Honor\u00e9","year":"2012","unstructured":"Honor\u00e9 PM et al (2012) New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif 33:44\u201351","journal-title":"Blood Purif"},{"key":"165_CR53","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/039139880502800803","volume":"28","author":"JV Di Carlo","year":"2005","unstructured":"Di Carlo JV, Alexander SR (2005) Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 28:777\u2013786","journal-title":"Int J Artif Organs"},{"key":"165_CR54","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/00003246-199306000-00022","volume":"21","author":"PA Lee","year":"1993","unstructured":"Lee PA, Matson JR, Pryor RW, Hinshaw LB (1993) Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 21:914\u2013924","journal-title":"Crit Care Med"},{"key":"165_CR55","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00000542-200108000-00027","volume":"95","author":"R Ullrich","year":"2001","unstructured":"Ullrich R et al (2001) Continuous venovenous hemofiltration improves arterial oxygenation in endotoxin-induced lung injury in pigs. Anesthesiology 95:428\u2013436","journal-title":"Anesthesiology"},{"key":"165_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0140-6736(00)02430-2","volume":"356","author":"C Ronco","year":"2000","unstructured":"Ronco C et al (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet Lond Engl 356:26\u201330","journal-title":"Lancet Lond Engl"},{"key":"165_CR57","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s001340100963","volume":"27","author":"L Cole","year":"2001","unstructured":"Cole L et al (2001) High-volume haemofiltration in human septic shock. Intensive Care Med 27:978\u2013986","journal-title":"Intensive Care Med"},{"key":"165_CR58","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-013-2967-z","volume":"39","author":"O Joannes-Boyau","year":"2013","unstructured":"Joannes-Boyau O et al (2013) High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 39:1535\u20131546","journal-title":"Intensive Care Med"},{"issue":"3","key":"165_CR59","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ndt\/gfr486","volume":"27","author":"P Zhang","year":"2012","unstructured":"Zhang P et al (2012) Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transplant. 27(3):967\u2013973","journal-title":"Nephrol Dial Transplant."},{"key":"165_CR60","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/cc13184","volume":"18","author":"E Clark","year":"2014","unstructured":"Clark E et al (2014) High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis. Crit Care Lond Engl 18:R7","journal-title":"Crit Care Lond Engl"},{"issue":"1","key":"165_CR61","first-page":"CD008075","volume":"1","author":"E.M Borthwick","year":"2017","unstructured":"Borthwick E.M et al (2017) High-volume haemofiltration for sepsis in adults. Cochrane Database Syst. Rev 1(1):CD008075","journal-title":"Cochrane Database Syst. Rev"},{"key":"165_CR62","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/01.CCM.0000114997.39857.69","volume":"32","author":"JA Kellum","year":"2004","unstructured":"Kellum JA, Song M, Venkataraman R (2004) Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 32:801\u2013805","journal-title":"Crit Care Med"},{"key":"165_CR63","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/CCM.0b013e318170b9a7","volume":"36","author":"Z-Y Peng","year":"2008","unstructured":"Peng Z-Y, Carter MJ, Kellum JA (2008) Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 36:1573\u20131577","journal-title":"Crit Care Med"},{"key":"165_CR64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13054-017-1662-9","volume":"21","author":"K Kogelmann","year":"2017","unstructured":"Kogelmann K, Jarczak D, Scheller M, Dr\u00fcner M (2017) Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care Lond Engl 21:74","journal-title":"Crit Care Lond Engl"},{"key":"165_CR65","doi-asserted-by":"publisher","first-page":"e0187015","DOI":"10.1371\/journal.pone.0187015","volume":"12","author":"D Sch\u00e4dler","year":"2017","unstructured":"Sch\u00e4dler D et al (2017) The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS ONE 12:e0187015","journal-title":"PLoS ONE"},{"key":"165_CR66","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00063-017-0342-5","volume":"114","author":"S Friesecke","year":"2019","unstructured":"Friesecke S et al (2019) International registry on the use of the CytoSorb\u00ae adsorber in ICU patients\u202f: Study protocol and preliminary results. Med Klin Intensivmed Notfallmedizin 114:699\u2013707","journal-title":"Med Klin Intensivmed Notfallmedizin"},{"issue":"3","key":"165_CR67","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10047-017-0967-4","volume":"20","author":"S Friesecke","year":"2017","unstructured":"Friesecke S, Stecher S-S, Gross S, Felix SB, Nierhaus A (2017) Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J. Artif. Organs. 20(3):252\u2013259","journal-title":"J. Artif. Organs."},{"key":"165_CR68","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445\u20132452","journal-title":"JAMA"},{"key":"165_CR69","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","volume":"41","author":"DM Payen","year":"2015","unstructured":"Payen DM et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41:975\u2013984","journal-title":"Intensive Care Med"},{"key":"165_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173633","volume":"12","author":"N Saito","year":"2017","unstructured":"Saito N et al (2017) Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection. PLoS ONE 12:e0173633","journal-title":"PLoS ONE"},{"key":"165_CR71","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/CCM.0000000000002362","volume":"45","author":"T Chang","year":"2017","unstructured":"Chang T et al (2017) Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis. Crit Care Med 45:e858\u2013e864","journal-title":"Crit Care Med"},{"key":"165_CR72","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP et al (2018) Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA 320:1455\u20131463","journal-title":"JAMA"},{"key":"165_CR73","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"DJ Klein","year":"2018","unstructured":"Klein DJ et al (2018) Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med 44:2205\u20132212","journal-title":"Intensive Care Med"},{"key":"165_CR74","doi-asserted-by":"publisher","first-page":"180243","DOI":"10.1038\/sdata.2018.243","volume":"5","author":"M Hayakawa","year":"2018","unstructured":"Hayakawa M et al (2018) Nationwide registry of sepsis patients in Japan focused on disseminated intravascular coagulation 2011\u20132013. Sci Data 5:180243","journal-title":"Sci Data"},{"key":"165_CR75","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13054-023-04533-3","volume":"27","author":"I Osawa","year":"2023","unstructured":"Osawa I et al (2023) Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial. Crit Care Lond Engl 27:245","journal-title":"Crit Care Lond Engl"},{"key":"165_CR76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00134-017-5004-9","volume":"44","author":"T Fujii","year":"2018","unstructured":"Fujii T et al (2018) Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis\/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 44:167\u2013178","journal-title":"Intensive Care Med"},{"key":"165_CR77","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00134-003-1724-0","volume":"29","author":"M Formica","year":"2003","unstructured":"Formica M et al (2003) Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock. Intensive Care Med 29:703\u2013708","journal-title":"Intensive Care Med"},{"key":"165_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003536","volume":"4","author":"S Livigni","year":"2014","unstructured":"Livigni S et al (2014) Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 4:e003536","journal-title":"BMJ Open"},{"key":"165_CR79","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000360268","volume":"37","author":"G Berlot","year":"2014","unstructured":"Berlot G et al (2014) Effects of the volume of processed plasma on the outcome, arterial pressure and blood procalcitonin levels in patients with severe sepsis and septic shock treated with coupled plasma filtration and adsorption. Blood Purif 37:146\u2013151","journal-title":"Blood Purif"},{"key":"165_CR80","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000490611","volume":"46","author":"G Berlot","year":"2018","unstructured":"Berlot G et al (2018) Influence of Timing of Initiation and Volume of Processed Plasma on the Outcome of Septic Shock Patients Treated with Coupled Plasma Filtration and Adsorption. Blood Purif 46:274\u2013278","journal-title":"Blood Purif"},{"issue":"11","key":"165_CR81","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-021-06501-3","volume":"47","author":"E Garbero","year":"2021","unstructured":"Garbero E et al (2021) High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med 47(11):1303\u20131311","journal-title":"Intensive Care Med"},{"key":"165_CR82","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/cc10597","volume":"16","author":"M Shankar-Hari","year":"2012","unstructured":"Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M (2012) Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care Lond Engl 16:206","journal-title":"Crit Care Lond Engl"},{"key":"165_CR83","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nri2849","volume":"10","author":"MR Ehrenstein","year":"2010","unstructured":"Ehrenstein MR, Notley CA (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10:778\u2013786","journal-title":"Nat Rev Immunol"},{"key":"165_CR84","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/joim.12265","volume":"276","author":"JF Bermejo-Mart\u00edn","year":"2014","unstructured":"Bermejo-Mart\u00edn JF et al (2014) Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med 276:404\u2013412","journal-title":"J Intern Med"},{"key":"165_CR85","doi-asserted-by":"publisher","first-page":"R247","DOI":"10.1186\/cc13073","volume":"17","author":"EJ Giamarellos-Bourboulis","year":"2013","unstructured":"Giamarellos-Bourboulis EJ et al (2013) Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care Lond Engl 17:R247","journal-title":"Crit Care Lond Engl"},{"key":"165_CR86","first-page":"2677","volume":"35","author":"KG Kreymann","year":"2007","unstructured":"Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35:2677\u20132685","journal-title":"Crit Care Med"},{"key":"165_CR87","first-page":"1","volume":"16","author":"MO Soares","year":"2012","unstructured":"Soares MO et al (2012) An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess Winch Engl 16:1\u2013186","journal-title":"Health Technol Assess Winch Engl"},{"key":"165_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001090.pub2","author":"MM Alejandria","year":"2013","unstructured":"Alejandria MM, Lansang MAD, Dans LF, Iii JBM (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001090.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"165_CR89","first-page":"559","volume":"82","author":"S Busani","year":"2016","unstructured":"Busani S, Damiani E, Cavazzuti I, Donati A, Girardis M (2016) Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. Minerva Anestesiol 82:559\u2013572","journal-title":"Minerva Anestesiol"},{"key":"165_CR90","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1097\/00003246-200712000-00026","volume":"35","author":"K Werdan","year":"2007","unstructured":"Werdan K et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693\u20132701","journal-title":"Crit Care Med"},{"key":"165_CR91","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801\u2013810","journal-title":"JAMA"},{"key":"165_CR92","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/376630","volume":"37","author":"J Darenberg","year":"2003","unstructured":"Darenberg J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis Off Publ Infect Dis Soc Am 37:333\u2013340","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"165_CR93","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/cid\/ciu449","volume":"59","author":"A Linn\u00e9r","year":"2014","unstructured":"Linn\u00e9r A, Darenberg J, Sj\u00f6lin J, Henriques-Normark B, Norrby-Teglund A (2014) Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis Off Publ Infect Dis Soc Am 59:851\u2013857","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"165_CR94","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00134-017-4786-0","volume":"43","author":"MB Madsen","year":"2017","unstructured":"Madsen MB et al (2017) Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med 43:1585\u20131593","journal-title":"Intensive Care Med"},{"key":"165_CR95","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/cid\/ciw871","volume":"64","author":"SS Kadri","year":"2017","unstructured":"Kadri SS et al (2017) Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis Off Publ Infect Dis Soc Am 64:877\u2013885","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"165_CR96","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00134-018-5143-7","volume":"44","author":"T Welte","year":"2018","unstructured":"Welte T et al (2018) Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med 44:438\u2013448","journal-title":"Intensive Care Med"},{"key":"165_CR97","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00134-017-4957-z","volume":"44","author":"C Tascini","year":"2018","unstructured":"Tascini C et al (2018) Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease. Intensive Care Med 44:261\u2013262","journal-title":"Intensive Care Med"},{"key":"165_CR98","doi-asserted-by":"publisher","first-page":"302","DOI":"10.23736\/S0375-9393.16.11268-4","volume":"83","author":"C Rouget","year":"2017","unstructured":"Rouget C et al (2017) Biological markers of injury-induced immunosuppression. Minerva Anestesiol 83:302\u2013314","journal-title":"Minerva Anestesiol"},{"key":"165_CR99","first-page":"499","volume":"22","author":"EJ Giamarellos-Bourboulis","year":"2016","unstructured":"Giamarellos-Bourboulis EJ et al (2016) Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 22:499\u2013506","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"165_CR100","first-page":"2808203","volume":"2017","author":"S Busani","year":"2017","unstructured":"Busani S et al (2017) The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR\/XDR Infections. Can. J. Infect. Dis. Med. Microbiol. J. Can. Mal. Infect. Microbiol. Medicale 2017:2808203","journal-title":"Can. J. Infect. Dis. Med. Microbiol. J. Can. Mal. Infect. Microbiol. Medicale"},{"key":"165_CR101","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/01.CCM.0000215452.84291.C6","volume":"34","author":"M Hentrich","year":"2006","unstructured":"Hentrich M et al (2006) IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 34:1319\u20131325","journal-title":"Crit Care Med"},{"key":"165_CR102","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13613-018-0466-7","volume":"8","author":"G Berlot","year":"2018","unstructured":"Berlot G et al (2018) Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients. Ann Intensive Care 8:122","journal-title":"Ann Intensive Care"},{"key":"165_CR103","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00134-003-1666-6","volume":"29","author":"A Nierhaus","year":"2003","unstructured":"Nierhaus A et al (2003) Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 29:646\u2013651","journal-title":"Intensive Care Med"},{"key":"165_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003039.pub2","author":"R Mhaskar","year":"2014","unstructured":"Mhaskar R et al (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003039.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"77","key":"165_CR105","first-page":"2366","volume":"1985","author":"PQ Eichacker","year":"1994","unstructured":"Eichacker PQ et al (1994) Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol Bethesda Md 1985(77):2366\u20132373","journal-title":"J Appl Physiol Bethesda Md"},{"issue":"3","key":"165_CR106","first-page":"CD003066","volume":"2003","author":"R Carr","year":"2003","unstructured":"Carr R, Modi N, Dor\u00e9 C (2003) G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst. Rev 2003(3):CD003066","journal-title":"Cochrane Database Syst. Rev"},{"key":"165_CR107","doi-asserted-by":"publisher","first-page":"R58","DOI":"10.1186\/cc10031","volume":"15","author":"L Bo","year":"2011","unstructured":"Bo L, Wang F, Zhu J, Li J, Deng X (2011) Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care Lond Engl 15:R58","journal-title":"Crit Care Lond Engl"},{"key":"165_CR108","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","volume":"180","author":"C Meisel","year":"2009","unstructured":"Meisel C et al (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180:640\u2013648","journal-title":"Am J Respir Crit Care Med"},{"key":"165_CR109","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/CCM.0b013e31822d7bf0","volume":"40","author":"R Paine","year":"2012","unstructured":"Paine R et al (2012) A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 40:90\u201397","journal-title":"Crit Care Med"},{"key":"165_CR110","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/thoraxjnl-2017-211323","volume":"73","author":"EM Pinder","year":"2018","unstructured":"Pinder EM et al (2018) Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis. Thorax 73:918\u2013925","journal-title":"Thorax"},{"issue":"19","key":"165_CR111","doi-asserted-by":"publisher","first-page":"e33770","DOI":"10.1097\/MD.0000000000033770","volume":"102","author":"J Sun","year":"2023","unstructured":"Sun J, Zhang X, Ma L, Yang Y, Li X (2023) Clinical study of rhGM-CSF for the treatment of pulmonary exogenous acute respiratory distress syndrome by modulating alveolar macrophage subtypes: A randomized controlled trial. Medicine (Baltimore) 102(19):e33770","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"165_CR112","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/liv.15534","volume":"43","author":"V Prakash","year":"2023","unstructured":"Prakash V, Arora V, Jindal A, Maiwall R, Sarin SK (2023) Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult-to-treat spontaneous bacterial peritonitis: A randomized controlled trial. Liver Int. 43(6):1298\u20131306","journal-title":"Liver Int."},{"key":"165_CR113","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00005-016-0415-9","volume":"65","author":"M Prucha","year":"2017","unstructured":"Prucha M, Zazula R, Russwurm S (2017) Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment? Arch Immunol Ther Exp (Warsz) 65:37\u201349","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"5","key":"165_CR114","doi-asserted-by":"publisher","first-page":"e98960","DOI":"10.1172\/jci.insight.98960","volume":"3","author":"B Francois","year":"2018","unstructured":"Francois B et al (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3(5):e98960","journal-title":"JCI Insight"},{"key":"165_CR115","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/infdis\/jis383","volume":"206","author":"J Unsinger","year":"2012","unstructured":"Unsinger J et al (2012) Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 206:606\u2013616","journal-title":"J Infect Dis"},{"issue":"189","key":"165_CR116","first-page":"5073","volume":"1950","author":"F Venet","year":"2012","unstructured":"Venet F et al (2012) IL-7 restores lymphocyte functions in septic patients. J Immunol Baltim Md 1950(189):5073\u20135081","journal-title":"J Immunol Baltim Md"},{"key":"165_CR117","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/SHK.0000000000000317","volume":"43","author":"Y Shindo","year":"2015","unstructured":"Shindo Y, Unsinger J, Burnham C-A, Green JM, Hotchkiss RS (2015) Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock Augusta Ga 43:334\u2013343","journal-title":"Shock Augusta Ga"},{"key":"165_CR118","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13613-023-01109-w","volume":"13","author":"T Daix","year":"2023","unstructured":"Daix T et al (2023) Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care 13:17","journal-title":"Ann Intensive Care"},{"key":"165_CR119","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/01.ccm.0000529506.43290.de","volume":"46","author":"R Hotchkiss","year":"2018","unstructured":"Hotchkiss R et al (2018) 1504: Immune Checkpoint Inhibitors In Sepsis: A Phase 1B Trial Of Anti-PD-L1 (BMS-936559). Crit Care Med 46:736","journal-title":"Crit Care Med"},{"key":"165_CR120","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1189\/jlb.4HI0616-255R","volume":"100","author":"AC Patera","year":"2016","unstructured":"Patera AC et al (2016) Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol 100:1239\u20131254","journal-title":"J Leukoc Biol"},{"key":"165_CR121","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","volume":"17","author":"D Grimaldi","year":"2017","unstructured":"Grimaldi D, Pradier O, Hotchkiss RS, Vincent J-L (2017) Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis. Lancet Infect Dis 17:18","journal-title":"Lancet Infect Dis"},{"key":"165_CR122","doi-asserted-by":"publisher","first-page":"e1727","DOI":"10.1542\/peds.2014-2175","volume":"134","author":"G Valentine","year":"2014","unstructured":"Valentine G, Thomas TA, Nguyen T, Lai Y-C (2014) Chronic granulomatous disease presenting as hemophagocytic lymphohistiocytosis: a case report. Pediatrics 134:e1727\u20131730","journal-title":"Pediatrics"},{"key":"165_CR123","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","volume":"19","author":"D Payen","year":"2019","unstructured":"Payen D et al (2019) Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series BMC Infect Dis 19:931","journal-title":"A case series BMC Infect Dis"},{"key":"165_CR124","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00134-023-07065-0","volume":"49","author":"A Roquilly","year":"2023","unstructured":"Roquilly A et al (2023) Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial. Intensive Care Med 49:530\u2013544","journal-title":"Intensive Care Med"}],"container-title":["Journal of Anesthesia, Analgesia and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-024-00165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44158-024-00165-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-024-00165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T09:40:33Z","timestamp":1731836433000},"score":1,"resource":{"primary":{"URL":"https:\/\/janesthanalgcritcare.biomedcentral.com\/articles\/10.1186\/s44158-024-00165-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1186\/s44158-024-00165-3","relation":{},"ISSN":["2731-3786"],"issn-type":[{"value":"2731-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"28 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MG: speaker honoraria and\/or consultant activity from Biotest, Estor, Fresenius, Viatris; SDR: speaker honoraria and\/or consultant activity from Baxter, Biotest, Estor, Fresenius, Toray; KD: speaker honoraria from Biotest; GG: speaker honoraria and\/or consultant activity from Pfizer, Viatris, Biotest; SR: speaker honoraria and consultant activity from Baxter and Biotest. All the other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}